Doxylamine
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Doxylamine: From Insomnia & Nausea Relief to Allergic Urticaria
One-Sentence Summary
Doxylamine is a first-generation H1 histamine receptor antagonist, historically used over-the-counter as a sleep aid and (combined with pyridoxine) for nausea and vomiting of pregnancy. The TxGNN model predicts it may be effective for Allergic Urticaria, with a prediction confidence of 99.85%; however, 0 clinical trials and 0 publications specifically supporting this repurposing direction were identified — the rationale rests entirely on pharmacological mechanism inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Insomnia; nausea and vomiting of pregnancy (based on established pharmacological use; no India registration on record) |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L4 |
| India Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from this Evidence Pack. Based on established pharmacological knowledge, Doxylamine is a first-generation H1 histamine receptor antagonist with additional anticholinergic and central sedative properties — belonging to the ethanolamine subclass of antihistamines.
Allergic urticaria is a quintessential histamine-driven condition: allergen exposure triggers IgE-mediated mast cell degranulation, releasing histamine that binds cutaneous H1 receptors to produce the characteristic wheal-and-flare response, pruritus, and angioedema. H1 receptor antagonists directly block this pathophysiological cascade at the molecular level, and the EAACI/GA²LEN international guidelines establish antihistamines as the unequivocal first-line therapy for allergic urticaria. The mechanistic link between Doxylamine and this indication is therefore pharmacologically direct and scientifically sound.
The primary clinical caveat is competitive displacement by second-generation antihistamines (cetirizine, loratadine, fexofenadine), which share the same H1 mechanism but lack the significant sedation and anticholinergic burden inherent to Doxylamine. Unless a specific patient subpopulation benefit can be identified — such as patients who benefit from the combined sedative-antihistamine profile — Doxylamine faces a high barrier for clinical prioritisation over existing alternatives. No Doxylamine-specific clinical trials or publications for allergic urticaria were found in this evidence search.
Clinical Trial Evidence
Currently no related clinical trials registered for Doxylamine in allergic urticaria.
Literature Evidence
Currently no related literature available for Doxylamine specifically in allergic urticaria.
India Market Information
Doxylamine currently has no approved drug registrations in the India market. No license records are available.
Safety Considerations
Drug Interactions (289 total interactions identified; key interactions listed below):
| Severity | Interacting Drug | Interaction Class |
|---|---|---|
| Major | Potassium citrate | Risk of GI mucosal injury / delayed transit |
| Major | Potassium chloride | Risk of GI mucosal injury / delayed transit |
| Moderate | Morphine | Additive CNS and respiratory depression |
| Moderate | Morphine (liposomal) | Additive CNS and respiratory depression |
| Moderate | Opium | Additive CNS depression |
| Moderate | Scopolamine | Additive anticholinergic toxicity |
| Moderate | Atropine | Additive anticholinergic toxicity |
| Moderate | Hyoscyamine | Additive anticholinergic toxicity |
| Moderate | Glycopyrronium | Additive anticholinergic toxicity |
| Moderate | Glycopyrronium (topical) | Additive anticholinergic toxicity |
| Moderate | Dicyclomine | Additive anticholinergic toxicity |
| Moderate | Mepenzolate | Additive anticholinergic toxicity |
| Moderate | Methscopolamine | Additive anticholinergic toxicity |
| Moderate | Propantheline | Additive anticholinergic toxicity |
| Moderate | Clidinium | Additive anticholinergic toxicity |
| Moderate | Metoclopramide | Pharmacodynamic antagonism (dopaminergic) |
| Moderate | Loperamide | Additive GI motility reduction |
| Moderate | Eluxadoline | Additive GI motility reduction |
| Moderate | Dronabinol | Additive CNS depression |
| Moderate | Nabilone | Additive CNS depression |
Note: Complete warnings and contraindications are unavailable in this Evidence Pack. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: While Doxylamine’s H1-antagonist mechanism provides a pharmacologically direct and textbook rationale for allergic urticaria, zero Doxylamine-specific clinical trials or publications were found, the evidence level is L4 (mechanistic inference only), and the therapeutic landscape is already well-served by second-generation antihistamines with superior tolerability profiles — creating a high bar for clinical differentiation.
To proceed, the following is needed:
- Retrieve and review the full Doxylamine package insert (warnings, contraindications, and formal MOA documentation) to complete the S1 safety gate
- Conduct a systematic comparative literature review of first-generation vs. second-generation antihistamines in urticaria to identify evidence gaps where Doxylamine could offer distinct value
- Define a target patient subpopulation hypothesis where the sedative-antihistamine dual profile is clinically advantageous (e.g., patients with urticaria-associated sleep disruption)
- If a viable niche is identified, design a pilot randomised controlled trial or observational study to generate Doxylamine-specific efficacy and tolerability data in allergic urticaria
- Clarify India regulatory pathway requirements before any clinical development investment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.